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Abstract: The highly attenuated Modified Vaccinia virus Ankara (MVA) lacks most of the known
vaccinia virus (VACV) virulence and immune evasion genes. Today MVA can serve as a safety-tested
next-generation smallpox vaccine. Yet, we still need to learn about regulatory gene functions
preserved in the MVA genome, such as the apoptosis inhibitor genes F1L and E3L. Here, we tested
MVA vaccine preparations on the basis of the deletion mutant viruses MVA-∆F1L and MVA-∆E3L for
efficacy against ectromelia virus (ECTV) challenge infections in mice. In non-permissive human tissue
culture the MVA deletion mutant viruses produced reduced levels of the VACV envelope antigen B5.
Upon mousepox challenge at three weeks after vaccination, MVA-∆F1L and MVA-∆E3L exhibited
reduced protective capacity in comparison to wildtype MVA. Surprisingly, however, all vaccines
proved equally protective against a lethal ECTV infection at two days after vaccination. Accordingly,
the deletion mutant MVA vaccines induced high levels of virus-specific CD8+ T cells previously
shown to be essential for rapidly protective MVA vaccination. These results suggest that inactivation
of the anti-apoptotic genes F1L or E3L modulates the protective capacity of MVA vaccination most
likely through the induction of distinct orthopoxvirus specific immunity in the absence of these viral
regulatory proteins.
Keywords: smallpox vaccination; MVA; immunogenic cell death; emergency vaccination
1. Introduction
Variola virus (VARV), the causative agent of human smallpox, has been successfully eradicated
by prophylactic vaccination using live vaccinia virus (VACV). However, even today more than thirty
years after this famous achievement in medicine, there are still concerns that VARV may be used as
bioterroristic weapon and zoonotic monkeypox or cowpox remain threatening infections in humans.
Thus, developing improved vaccination principles ready to use in an immediate public health response
are essential. The Modified Vaccinia virus Ankara (MVA) is a replication-deficient and safety tested
VACV that is already licensed as a next-generation smallpox vaccine in Europe and Canada. Moreover,
MVA has been actively investigated as a non-replicating multipurpose viral vector vaccine against
other infections and cancer diseases [1,2]. Thus, MVA is a promising platform to develop innovative
candidate vaccines inducing improved innate and adaptive immune responses. Scenarios of emergency
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immunization necessitate rapidly protective vaccination strategies. At best, this includes robust
activation of immunity by preferably low dose applications of the respective vaccine. In previous
studies, we and others confirmed the short-term protective capacity of low-dose MVA immunization in
animal models for lethal infections with orthopoxviruses. Probably the best animal model for studying
the protective capacity of new candidate orthopoxvirus-specific vaccines is the ectromelia virus-mouse
challenge model. Ectromelia virus (ECTV), the causative agent of mousepox, provides an excellent
surrogate model for human smallpox because a deadly systemic disease develops after inoculations
of very low doses of virus [3]. Mice that survive the acute phase of infection develop a pustular
rash on the skin, highly comparable to VARV infections in humans. Using the ECTV-mouse model,
we confirmed that MVA vaccination efficiently prevents disease and death in C57BL/6 mice after
lethal intranasal challenge infection [3–5]. However, with regard to the efficacy of immunization we
still know rather little about the influence of regulatory gene functions preserved in the MVA genome.
Indeed, inactivation of several MVA regulatory gene functions has already been confirmed as a strategy
to further enhance immunogenicity and vaccine induced protective capacity [6,7]. More recently, viral
proteins known to counteract induction of apoptosis [8–11] are amongst the most promising candidate
targets for potential optimization of MVA as a vaccine. Programmed cell death as a trigger for enhanced
immunogenicity can be explained by different mechanisms. Well-established is the hypothesis that
apoptotic cells will be processed by dendritic cells resulting in an increased major histocompatibility
complex (MHC) class I presentation for enhanced immunogenicity. In previous studies this so-called
cross presentation has been proposed as the most important mechanism for antigen presentation upon
primary immunization to induce efficient T-cell response [12]. In the context of cancer therapy, recent
studies support the concept of the so called immunogenic cell death (ICD). ICD is another form of
cell death that is reported to efficiently trigger an immune response against antigens associated with
the dying cell. ICD has been initially identified when studying immune defense mechanisms against
cancer cells. Here, the immunogenic death of cancer cells efficiently activated an effective antitumor
immune response through antigen presentation by dendritic cells (DCs) and, consequently, activation
of tumor-specific T cells. It has been hypothesized, that also virus infected cells might respond via
this immunogenic form of apoptosis to counteract an infection. Of note, different from the tolerogenic,
physiological cell death, ICD also triggers the activation of innate immunity including a wide range
of proinflammatory cytokines and binding to pattern recognition receptors (PRRs) such as Toll-like
receptor (TLR) 2 and 4 [13]. This will then further allow for enhanced activation of the adaptive
immune responses [14,15]. Enhanced immunogenicity is reported for DNA vaccines with capacity
to actively induce apoptosis [16,17], and improved antiviral immune responses are described for a
dendritic cell vaccine against high grade glioma [13]. For VACV, several immune evasion proteins
involved in inhibition of apoptosis/cell death have been identified. Of these, the open reading frames
(ORF) E3L and F1L are functionally retained in the MVA genome [18–22]. VACV F1 protein acts in
inhibiting the intrinsic pathway of apoptosis by localizing to the outer mitochondria membrane and
repressing cytochrome C release. F1 targets the BH3-only protein Bim and prevents the activation
of pro-apoptotic Bcl-2 family members Bak and Bax [11,23]. Once activated, these proteins play
an important role for the activation of specific signal transduction pathways in the mitochondrial
apoptotic effector machinery, resulting in the release of pro-apoptotic mediators like cytochrome c
and subsequently in cell death [24]. The F1L gene encoding sequences are highly conserved among
orthopoxviruses. In previous studies, deletion of the F1L gene in the VACV or MVA genome has
been confirmed to enhance the induction of apoptosis after in vitro infection using different cell
lines [19,23]. The VACV E3L gene encodes for a 25 kDa protein that features an amino-terminal
Z-DNA-binding domain and a carboxyl-terminal RNA-binding domain. The carboxyterminal domain
has been shown to inhibit double-stranded RNA (dsRNA)-activated protein kinase (PKR) by binding
and sequestering dsRNA produced during VACV life cycle. Another function of the E3 polypeptide is
to block phosphorylation and thus activation of interferon (IFN) regulatory factor 3 (IRF3) and IRF7,
required for viral induction of IFN-α/β. In previous studies, an MVA E3L deletion mutant (MVA-∆E3L)
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was found replication-deficient in chicken embryo fibroblasts (CEF) resulting in insufficient viral
DNA and protein synthesis, enhanced induction of apoptosis, and increased production of chicken
IFN-α/β [20]. The advantageous immunomodulatory properties of MVA vaccines are most likely
based on the inactivation of VACV immune evasion genes that counteract the host immune response [2].
Thus, enhancing a potential MVA-mediated immunogenic cell death by inactivation of the F1L or E3L
gene functions could be a promising approach to further improve the efficacy of MVA vaccination.
However, the anti-apoptotic viral genes F1L and E3L are functional in MVA genome and the deletion
of these genes also impairs the synthesis of late viral antigen in human and murine cells [20–22],
and, therefore, their inactivation might lessen the efficacy of vaccination. To address this question,
we generated and quality controlled vaccine preparations on the basis of the deletion mutant viruses
MVA-∆F1L and MVA-∆E3L. As expected, the MVA deletion mutant vaccine viruses produced reduced
levels of the VACV envelope antigen B5 upon tissue culture infection. When testing the candidate
vaccines in the C57BL/6 mouse ECTV challenge model, the MVA vaccines lacking E3L or F1L genes
exhibited reduced protective capacity in comparison to the MVA control vaccine at three weeks after
single shot vaccination. Surprisingly, however, we found all vaccines equally efficient for rapidly
protective immunization against a lethal ECTV challenge infection given two days after vaccination.
In accordance with this finding, the deletion mutant MVA vaccines induced high levels virus-specific
CD8+ T cells previously shown to be essential for rapidly protective MVA vaccination. These results
suggest that inactivation of the anti-apoptotic genes F1L or E3L modulates the protective capacity of
MVA vaccination against ECTV infection most likely through the induction of distinct orthopoxvirus
specific immunity in the absence of these viral regulatory proteins.
2. Materials and Methods
2.1. Cells and Viruses
MA-104 (ATCC CCL-26), HeLa (ATCC CCL-2), NIH/3T3 (ATCC CRL-1658), BHK-21 (ATCC
CCL-10) and chicken embryo fibroblast (CEF) cells were used and routinely maintained as previously
described. Plaque purified Ectromelia virus (ECTV) strain Moscow (ATCC VR-1374, kindly provided
by Mark L. Buller, St. Louis University School of Medicine, St. Louis, MI, USA) was propagated
on MA-104 cells. As experimental vaccine served Modified Vaccinia virus Ankara (MVA) (clonal
isolate F6; MVA F6) [25]; all recombinant, mutant and revertant viruses were derived from MVA F6.
MVA-∆E3L, MVA-∆F1L and the corresponding revertant viruses were generated and characterized as
described previously [19–22]. Viruses were routinely propagated and titrated on CEF or BHK-21 cells.
Viral titers were determined by plaque assay and titrated in plaque forming units (pfu) as previously
described [26].
2.2. Western Blot Analysis
Confluent monolayers of HeLa cells or NIH/3T3 cells were infected at a multiplicity of infection
(MOI) of 5 with Modified Vaccinia virus Ankara (MVA) (clonal isolate F6), MVA-∆F1L, MVA-∆E3L
and revertant viruses. Cell lysates were prepared at different time points after infection (3, 6, 9,
15 h post-infection (hpi). Lysates from uninfected cells or wild-type MVA-infected cells served as
controls. Polypeptides were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) and electroblotted onto a polyvinylidene difluoride (PVDF) membrane. After blocking,
membranes were incubated with primary antibodies (rabbit anti-B5 diluted 1:500; rabbit anti-C7
diluted 1:1000; rabbit anti-poly(ADP-ribose)polymerase (PARP) Cell Signaling Technology (Danvers,
MA, USA) diluted 1:1000; mouse anti-β-Actin Sigma-Aldrich (St. Louis, MI, USA) diluted 1:1000) at
4 ◦C overnight. After washing, the blots were incubated with secondary antibodies for one hour at
room temperature.
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2.3. Northern Blot Analysis
For analysis of mRNA, cells were infected with MVA, MVA-∆E3L or the revertant virus
MVA-∆E3Lrev at an MOI of 5. PBS-infected cells served as mock-control. Total RNA was isolated with
TRIzol reagent (Invitrogen, Carlsbad, CA, USA), following the manufacturer’s instructions. Total RNA
was separated by electrophoresis in 1% agarose formaldehyde gels. Following, RNA was transferred
onto positively charged nylon membranes (Roche Diagnostics, Basel, Switzerland). Riboprobes for
detection of MVA-encoded 047R (F17R) mRNAs and reverse primers containing a T7-RNA polymerase
promoter were synthesized as previously described [21]. In vitro RNA labeling, hybridization,
and signal detection were carried out according to the manufacturer’s instructions (Digoxigenin-UTP
(DIG) RNA labeling kit and detection chemicals; Roche Diagnostics, Basel, Switzerland), applying
68 ◦C for prehybridization, hybridization, and high stringency washing.
2.4. Mice
Female C57BL/6N mice (6–10 weeks old) were purchased from Charles River Laboratories
(Sulzfeld, Germany). For experimental work, mice were housed in an isolated (ISO) cage unit
(Tecniplast, Hohenpeißenberg, Germany) and had free access to food and water. All animal
experiments were handled in compliance with the German regulations for animal experimentation
(Animal Welfare Act, approved by the Government of Upper Bavaria, Munich, Germany).
2.5. Immunization and Infection Experiments
Intramuscular (i.m.) vaccination was performed by injection of 50 µL of virus suspension
containing 105 or 106 pfu of MVA, MVA-∆F1L, MVA-∆E3L or phosphate-buffered saline (PBS) into
the left hind leg. For intranasal infection, mice were anesthesized by intraperitoneal (i.p.) injection
with 1 mg ketamine and 0.04 mg xylazine per 10 g body weight. Intranasal infection was performed
by instillation of 20 µL of virus suspension containing 200 pfu (~3 × LD50) or 2000 pfu (~30 × LD50)
ECTV. Signs of illness, weight loss and survival were monitored daily for at least three weeks. In all
experiments inoculations of corresponding amounts of PBS were used as controls (mock vaccine).
2.6. Analysis of MVA-Specific Antibodies
Firstly, 96-well immunoplates (Nunc-ImmunoTM MicroWellTM 96 well solid plates, Sigma-Aldrich,
Munich, Germany) were coated with 2 µg/mL sucrose gradient-purified MVA F6 in coating buffer
(70 mM NaHCO3, 30 mM Na2CO3, pH 9.6) for 3 h at 37 ◦C and overnight at 4 ◦C. After blocking with
PBS supplemented with 10% heat-inactivated fetal calf serum and 0.05% Tween-20, the plates were
incubated with serial dilutions of sera from immunized mice. Antibody titers were determined using an
alkaline-phosphatase conjugated anti-mouse antibody and p-nitrophenyl phosphate (Sigma-Aldrich,
Munich, Germany) as substrate.
2.7. Analysis of MVA Neutralizing Antibodies
For analysis of MVA neutralizing antibodies we used the reference clonal isolate MVA F6
purified by ultracentrifugation through sucrose cushions. Serum samples from immunized animals or
mock-vaccinated animals were tested in duplicate or triplicate in plaque reduction assays on CEF cell
monolayers grown in 24-well tissue culture plates. Eight two-fold serial dilutions of serum were mixed
with 200 pfu of MVA F6 at 37 ◦C for 2 h. Following incubation, 100 µL of the reaction mix was loaded
onto the CEF cell monolayers. Cells were over-laid with medium and incubated at 37 ◦C with 5% CO2
for 48 h. In the following media were removed and the cells were fixed with ice-cold methanol-aceton
for 5 min. Fixed cell monolayers were immunostained using primary rabbit anti-VACV antibody
(diluted 1:2000) and secondary antibody (peroxidase labeled goat anti-rabbit-Ig, Dianova, Hamburg,
Germany) followed by incubation with True Blue Peroxidase Reagent (KPL, medac GmbH, Wedel,
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Germany). Blue plaques were counted and MVA neutralization titers were determined to be the last
dilution of serum that reduced the number of plaques by 60% compared with control wells.
2.8. Analysis of Antigen-Specific CD8+ T Cells by Enzyme-Linked Immunospot Assay (ELISPOT)
Mice were sacrificed 8 or 56 days post-immunization. A cell suspension was prepared by
homogenizing the spleens through 200-µm mesh sieves, and red blood cells were removed by adding
red cell lysis buffer (Sigma, St. Louis, MI, USA). After centrifugation, the cell pellet was dissolved
in Roswell Park Memorial Institute (RPMI) medium supplemented with 10% fetal calf serum, 2 mM
L-glutamine and 100 IU/mL penicillin-streptomycin. Interferon gammas (IFN-γ)-secreting CD8+ T
cells were analyzed by using the Enzyme Linked Immuno Spot Assay (ELISPOT) PLUS kit for mouse
IFN-γ (MABTECH, SE-131 28 Nacka Strand, Sweden) following the manufacturer’s instructions.
ELISPOT plates were preincubated overnight with the antibody solution and then incubated with the
cell suspension that had been stimulated with the virus-specific peptide B8R20–27 (TSYKFESV, [27]).
The spots were counted and analyzed by using an automated ELISPOT plate reader and software
following the manufacturer’s instructions (A.EL.VIS Eli.Scan software; A.EL.VIS, Hanover, Germany).
2.9. Statistical Analysis
Statistical comparison of different groups of mice was analyzed by one-factorial analysis of
variance (ANOVA) for the area under the percentage-of-initial-weight curves (AUC). The differences
between vaccination groups were analyzed with a one-factorial analysis of variance model.
For multiple comparisons, P values were adjusted with the Bonferroni method. CD8+ T cell responses
were compared by T test. The statistical evaluation was performed with GraphPad Prism for Windows
(GraphPad Prism Software, La Jolla, CA, USA).
3. Results
3.1. Decreased Synthesis of the Late Viral Protein B5 in the Absence of E3L or F1L Gene Expression
Activation of the MVA life cycle in most host cells results in the synthesis of all classes
(early, intermediate, and late) of VACV proteins. Among the viral early proteins are antigens
containing important determinants of T cell immunity that are presented via MHC-I molecules
to CD8+ T cells [27,28]. Late viral proteins include surface antigens that are key targets of VACV
neutralizing antibodies such as B5 a major surface protein of extracellular VACV virions [29]. Thus,
we monitored the production of the viral protein B5 in HeLa cells infected with MVA, MVA-∆F1L or
MVA-∆E3L by Western blot analysis. The revertant viruses MVA-∆F1Lrev and MVA-∆E3Lrev served
as additional controls. As shown by the monitoring for cleaved poly-ADP ribose polymerase (PARP),
the characteristic induction of apoptosis in cells infected with MVA-∆F1L is reversed upon infection
with the revertant virus (Figure 1A). Similarly, the revertant virus MVA-∆E3Lrev overturned the failure
of MVA-∆E3L to proceed to late gene expression upon the infection of HeLa cells as demonstrated
by the Northern blot detection of significant amounts of late mRNA specific for the MVA gene 047R
(F17R) (Figure 1B). Previous work had already demonstrated that MVA-∆E3L is deficient in late
protein production in murine and human cells [21,22]. Thus, as expected, we easily found B5 in the
lysates of cells infected with MVA or the revertant viruses at six and nine hpi, and, we failed to detect
B5 in the lysates of MVA-∆E3L infected cells (Figure 1C). Though our Western blot was at best a
semi-quantitative assay, the synthesis of B5 protein in MVA-∆F1L infected cells was apparent at six
and nine hpi; however, the amounts of B5 revealed with MVA-∆F1L were clearly reduced compared
to those detected with MVA or the revertant virus MVA-∆F1Lrev. To control for uniform infections
with MVA-∆E3L or the control viruses, and to confirm the unimpaired activation of viral early gene
expression, we also monitored for the synthesis of the early viral protein C7. At three, six, nine hpi,
as expected, we detected comparable levels of C7 protein in the lysates of HeLa cells infected with
MVA, MVA-∆E3L and MVA-∆E3Lrev. These results indicated that an inactivation of either the F1L or
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the E3L gene function does interfere with the synthesis of late but not early gene products in MVA





Figure 1. (A) Western blot analysis of deletion mutant virus MVA-ΔF1L-induced apoptosis in murine 
cells. Lysates of NIH/3T3 cells infected with Modified Vaccinia virus Ankara (MVA), MVA-ΔF1L or 
MVA-ΔF1Lrev at a multiplicity of infection (MOI) of 5 were prepared 15 hpi, proteins were separated 
by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotted 
against poly-ADP ribose polymerase (PARP)/PARPcl and β-Actin as loading control. (B) Inhibition 
of late gene expression in MVA-ΔE3L infected HeLa cells. Total RNA was isolated and viral late 
mRNA was monitored by Northern blotting, using riboprobes specific for MVA late gene 047R. (C) 
Western blot analysis of MVA proteins produced in HeLa cells. Lysates of cells infected with deletion 
mutant viruses MVA-ΔF1L and MVA-ΔE3L were prepared at three, six, or nine hpi. Polypeptides were 
separated by SDS–PAGE and tested by immunoblotting using specific polyclonal antibodies against 
vaccinia virus (VACV) B5 protein and VACV C7 protein. Lysates from uninfected cells (Mock) or 
wildtype MVA infected cells (MVA-WT) or revertant viruses (MVA-ΔF1Lrev, MVA-ΔE3Lrev) 
infected cells served as controls. Indicated on the left are the positions of the molecular weight 
markers in comparison to the ~45 kDa VACV B5 (B5) and ~17 kDa VACV C7 (C7) proteins. 
Figure 1. (A) Western blot analysis of deletion mutant virus MVA-∆F1L-induced apoptosis in murine
cells. Lysates of NIH/3T3 cells infected with Modified Vaccinia virus Ankara (MVA), MVA-∆F1L or
MVA-∆F1Lrev at a multiplicity of infection (MOI) of 5 were prepared 15 hpi, proteins were separated
by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotted against
poly-ADP ribose polymerase (PARP)/PARPcl and β-Actin as loading contr . (B) I hibition of late
gene expression in MVA-∆E3L infected HeLa cells. Total RNA was isolated and viral late mRNA was
monitored by Northern blotting, using riboprobes specific for MVA late gene 047R. (C) Wester blot
analysis of MVA proteins produced in HeLa cells. Lysates of cells infected with deletion mutant viruses
MVA-∆F1L and MVA-∆E3L were prepared at three, six, or nine hpi. Polypeptides were separated by
SDS–PAGE and tested by immunoblotting using specific polyclonal antibodies against vaccinia virus
(VACV) B5 protein and VACV C7 protein. Lysates from uninfected cells (Mock) or wildtype MVA
infected cells (MVA-WT) or revertant viruses (MVA-∆F1Lrev, MVA-∆E3Lrev) infected cells served as
controls. Indicated on the left are the positions of the molecular weight markers in comparison to the
~45 kDa VACV B5 (B5) and ~17 kDa VACV C7 (C7) proteins.
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3.2. Protective Capacity of MVA Deletion Viruses against Lethal Poxvirus Infections
To elucidate the role of the F1 and E3 proteins in protective immunization, we tested MVA-∆F1L
and MVA-∆E3L in the C57BL/6 mouse-ECTV challenge model [3–5,30]. Briefly, we intramuscularly
(i.m.) vaccinated mice with either 105 or 106 pfu MVA-∆F1L and MVA-∆E3L twenty-one days before
the high dose respiratory infection with ECTV (2000 pfu corresponding to about 30 × LD50) (Figure 2).
Control mice were mock vaccinated with PBS. In the groups receiving 106 pfu of MVA or MVA-∆F1L
vaccine all mice survived the harsh ECTV challenge infection. Interestingly, we observed a clearly
reduced protective capacity of MVA-∆E3L vaccination with only two out of five mice surviving
the challenge. Furthermore, we noticed differences among the groups when monitoring for signs
of disease following the ECTV infection. MVA vaccination induced robust protection against the
challenge without any signs of illness or detectable body weight loss. Immunization with MVA-∆F1L
prevented death of the mice. However, all vaccinated animals developed signs of mousepox disease
and suffered from about 10% body weight loss starting six days post infection (dpi). In MVA-∆E3L
vaccinated mice, the signs of disease were more severe and culminated with a loss of up to 15%
of the body weight at day eleven post infection. Inoculations with doses of 105 pfu of the MVA
vaccines resulted in a more pronounced but similar outcome with regard to the induction of protective
immunity against the high-dose ECTV infection. All mice that had been vaccinated with 105 pfu
MVA-∆E3L developed systemic mousepox disease with progressive body weight loss starting nine
dpi, and died or had to be euthanized until thirteen dpi. In contrast, vaccinations with 105 pfu of
either the MVA-∆F1L or MVA vaccine protected against lethal mousepox. MVA-∆F1L vaccinated mice,
however, developed severe signs of illness which correlated with the body weight loss. In contrast,
in MVA immunized mice we observed no obvious weight loss or signs of mousepox illness. Taken
together, our data indicate that in comparison to standard MVA, vaccination immunizations with the
MVA mutant viruses deleted in the regulatory genes F1L or E3L have a reduced capacity to induce
protective immunity against severe mousepox.
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3.3. MVA-ΔF1L or MVA-ΔE3L Vaccines Prime Unimpaired VACV-Specific CD8+ T-Cell Responses 
In previous work, we showed that vaccine induced virus specific CD8+ T cell responses are 
essential for rapidly protective vaccination with MVA or conventional vaccinia virus in the ECTV 
mouse challenge model [3]. Our data so far suggested a restricted capacity of MVA-ΔE3L and MVA-
ΔF1L vaccination to confer protection against lethal mousepox twenty-one days after vaccination. To 
further assess the candidate vaccine induced T cell responses we vaccinated C57BL/6 mice via the 
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Figure 2. Protective capacity of MVA vaccination against lethal mousepox virus infections. C57BL/6
mice were challenged with 2000 plaque forming units (pfu) ECTV 21 days after immunization with
MVA vaccine at a dose of 106 pfu (A) or a dose of 105 pfu (B) or PBS (mock vaccinated animals,
used as controls). In all experiments, weight loss of individual mice was monitored daily (three to
five per group). Error bars indicate standard errors of the means (SEMs), and the numbers of
surviving/total animals are given in parentheses. * p < 0.05; ** p < 0.01; *** p < 0.001. Data are
representative of two or three experiments.
3.3. MVA-∆F1L or MVA-∆E3L Vaccines Prime Unimpaired VACV-Specific CD8+ T-Cell Responses
In previous work, we showed that vaccine induced virus specific CD8+ T cell responses are
essential for rapidly protective vaccination with MVA or conventional vaccinia virus in the ECTV
mouse challenge model [3]. Our data so far suggested a restricted capacity of MVA-∆E3L and
MVA-∆F1L vaccination to confer protection against lethal mousepox twenty-one days after vaccination.
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To further assess the candidate vaccine induced T cell responses we vaccinated C57BL/6 mice via the
intramuscular route using 106 pfu of MVA, MVA-∆F1L or MVA-∆E3L and analysed VACV-specific
CD8+ T cells by IFN-γ-ELISPOT. Single intramuscular immunizations with all test vaccines induced
substantial levels of B8R20–27-epitope-specific CD8+ T cells with median absolute numbers of 3.15 × 103
IFN-γ spot forming cells (SFC) per 106 splenocytes. Of note, MVA, MVA-∆F1L and MVA-∆E3L
vaccines induced close to identical magnitudes of CD8+ T cell responses (Figure 3A,B). These data
suggest an unimpaired priming of orthopoxvirus-specific CD8+ T cells following immunization with
MVA-∆F1L or MVA-∆E3L. Of note, MVA and MVA-∆E3L vaccines elicited very comparable levels of
B8R20–27-epitope-specific memory CD8+ T cells as demonstrated by the IFN-γ-ELISPOT analysis of T
cell responses at 56 days after initial immunization (Figure 3C).
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Figure 3. Virus-specific CD8+ T cells elicited by MVA vaccination. C57BL/6 mice were inoculated
intramuscularly with 106 pfu MVA, MVA-∆F1L (A), MVA-∆E3L (B), or PBS. At eight days
post-vaccination, splenocytes were prepared, and B8R20–27-specific IFN-γ-producing CD8+ T cells
were measured by Enzyme Linked Immuno Spot Assay (ELISPOT). Virus-specific CD8+ T cell memory
responses elicited by MVA-WT, MVA-∆E3L vaccination or PBS in C57BL/6 mice (n = 3–6 per group)
(C). Splenocytes were prepared at 56 days after prime vaccination. B8R20–27–epitope-specific, IFN-γ
spot forming CD8+ T cells (IFN-γ SFC) were quantified by ELISPOT. Data are representative of two
similar experiments. *** p < 0.001; ns, not significant.
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3.4. Rapidly Protective Immunization with MVA Vaccines Deficient in E3L or F1L
A sought-after feature of next-generation smallpox vaccines is the capacity to elicit rapidly
protective immunity against severe orthopoxvirus infections. In previous work, we demonstrated
that even a low dose of MVA vaccine (105 pfu) is sufficient to robustly protect against a lethal dose of
ECTV inoculated only two days after immunization [3]. Thus, we also evaluated the MVA-∆F1L and
MVA-∆E3L candidate vaccines in this model for short-term protection by vaccination. C57BL/6 mice
received intramuscularly 105 pfu of either MVA, MVA-∆F1L, or MVA-∆E3L vaccine. Injections with
PBS served as mock vaccines. Two days after immunization, mice were intranasally inoculated with
ECTV (200 pfu corresponding to approximately 3 × LD50) [3,4]. As expected, mock-vaccinated control
mice developed systemic mousepox disease with progressive body weight loss and died within thirteen
days after challenge. In accordance with previous data, all mice vaccinated with MVA mounted high
level protective immunity to the ECTV challenge infection. Remarkably, also immunizations with the
MVA-∆E3L or MVA-∆F1L candidate vaccines fully protected against mousepox disease and death
without observation of any signs of illness or body weight-loss. These data clearly suggested that the
lack of the VACV proteins F1 and E3 did not influence the outcome of rapid protection against a lethal
systemic orthopoxvirus infection in the context of MVA vaccination (Figure 4).
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Figure 4. Short-term protective capacity of MVA vaccination against lethal mousepox virus challenge
infection. Groups of C57BL/6 mice (n = 5) were inoculated with 200 pfu ECTV two days after
immunization with 105 pfu of MVA, MVA-∆F1L, or MVA-∆E3L. PBS vaccinated animals (n = 3) served
as controls (Mock). In all experiments, weight loss of individual mice was monitored daily. Error bars
indicate standard errors of the means (SEMs), and the numbers of surviving/total animals are given in
parentheses. *** p < 0.001. Data are representative of two or three experiments.
4. iscussion
The replication-deficient and safety tested virus has been licensed as a third-generation
s allpox vaccine in Europe and in Canada to replace the conventional live vaccinia virus vaccines [31].
The purpose of this study was to evaluate the possibility for further improvement of MVA as smallpox
vaccine including the development of vaccines that confer rapid protection in a case of emergency.
Here, we used the ECTV mousepox odel to test the protective capacity of MVA vaccines lacking
the ability to produce the VACV regulatory proteins E3 or F1. These are among the most potent
VACV regulatory immune defense proteins being produced by MVA and target the activation of
host innate im une responses and the onset of apoptosis [2]. The E3L and F1L gene sequences are
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fully conserved in the MVA genome and the deletion mutant viruses MVA-∆F1L and MVA-∆E3L
demonstrate impaired viral life cycles and elicit increased levels of cell death in various cell types [19,20].
In particular, the expression of late viral genes is compromised and reduced amounts of MVA late
structural proteins are made upon infections with the mutant viruses. This phenotype is associated
with the inhibition of viral intermediate transcription in MVA-∆E3L infected HeLa cells [21,22]. Hereby,
the lack of the regulatory protein E3 results in an increased type I interferon response, the induction
of apoptosis, and an enhanced synthesis of other cytokines and chemokines [19,20,32,33]. These
findings are in line with a major function of VACV E3 to bind and sequester double-stranded RNA
(dsRNA), thereby preventing the activation of type I interferons and important interferon response
proteins such as PKR and 2′-5′ oligoadenylate synthetase (OAS) [34,35]. Correspondingly, a similar
enhancement of innate immune responses is observed with recombinant MVA engineered to express
excess amounts dsRNA early during infection and in the presence of a functional E3L gene [36].
Inevitably, the impaired late gene expression in MVA-∆E3L infections was likely to result in reduced
synthesis of MVA structural antigens. Indeed, when monitoring in vitro antigen production by our
MVA-∆F1L and MVA-∆E3L candidate vaccines we clearly demonstrate a decreased synthesis of the
VACV envelope antigen B5 in human HeLa cells (Figure 1C). As B5 is a relevant target protein for
virus-neutralizing antibodies in humans these results questioned the suitability of E3L and F1L gene
inactivations to increase MVA immunogenicity as a smallpox vaccine. Yet, on the other hand the
inactivation of the F1L gene in MVA is reported to enhance CD8+ T cell responses to the vector
delivered HIV-1 target antigens [37]. In our study, the inhibition of B5 antigen production was
clearly more pronounced in infections with MVA-∆E3L compared to MVA-∆F1L. This result is in
agreement with the distinct interruption of the molecular virus life cycle in MVA-∆E3L infected HeLa
cells (Figure 1B). The finding of reduced B5 production in MVA-∆F1L infection seems mostly the
consequence of enhanced apoptosis limiting the overall time and resources for viral protein synthesis
due to the absence of the anti-apoptotic protein F1. Thus, both deletion mutant viruses MVA-∆E3L and
MVA-∆F1L were expected to deliver reduced levels of VACV late structural antigens but also to exhibit
particular immunostimulatory features. In consequence, the ability of MVA-∆E3L and MVA-∆F1L to
elicit protective immunity against orthopoxvirus infections was unclear. To comparatively test the
protective capacity of the MVA vaccines we chose lethal infections of mice with ECTV, a learned animal
model for human smallpox. Of note, we used two different models of respiratory ECTV infections: (i) at
two days after vaccine inoculation a 200 pfu ECTV challenge (~3 × LD50) to test for rapidly protective
immunization, and (ii) at 21 days after vaccination a 2000 pfu ECTV challenge (~30 × LD50) resulting
in pronounced respiratory disease and early death of infected animals to evaluate the protective
capacity of a more conventional orthopoxvirus-specific immunization. The vaccines were given by
intramuscular inoculation (a route routinely used for immunization in humans) and at doses (105 or
106 pfu) that were known to be fully protective against mousepox virus challenge infection [3,5,30]
but are about 100-fold reduced compared to the usual dosage of MVA vaccines in humans [38,39].
Our findings in the model for conventional immunizations suggested, that MVA-∆E3L vaccination is
significantly less protective compared to vaccinations with MVA-∆F1L or MVA. This reduced protection
observed with MVA-∆E3L is likely best explained by the clearly impaired viral late gene expression
resulting in minor amounts of structural antigens and an insufficient activation of virus-specific
antibodies and T cells. In the model of the harsh 2000 pfu ECTV challenge infection vaccine induced
antibody responses are likely needed for protection. Indeed, virus-specific antibodies have been shown
to play a dominant role for protection against highly lethal orthopoxvirus challenge infections in
other mouse and monkey models [40–42]. Thus, we suspected delivery of an insufficient amount
of structural antigen as a possible explanation for the impaired protective efficacy of MVA-∆E3L
immunization. However, a standard comparison of antibody responses elicited in mice receiving 106
pfu MVA, MVA-∆F1L or MVA-∆E3L vaccine did not reveal differences in the levels of virus particle
binding or virus neutralizing antibodies (data not shown). Our failure seems to reflect the common
inability of standard immune monitoring assays to reveal correlates for vaccine-mediated protection
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in vivo. Clearly, more detailed studies are needed to identify the distinct correlate(s) of protection
induced by conventional MVA immunization in comparison to MVA-∆E3L in our ECTV mouse
challenge model. Orthopoxviruses induce complex antibody responses reactive against many diverse
antigens [42,43]. Therefore, we might have missed the crucial antibody response specificities targeting
critical antigens when using our standard immune monitoring assays based on the measurement
of MVA-binding or MVA-neutralizing antibodies. Moreover, besides antibody responses the likely
immunologic mechanisms underlying protection by VACV immunization are diverse including CD4+
and CD8+ T cells [44]. Since the essential relevance of cytotoxic CD8+ T cells for early control of primary
ECTV replication in C57BL/6 mice is well documented for MVA vaccination [3,4], we hypothesized
that the absence of anti-apoptotic F1 or E3 protein might inadvertently influence the activation of
CD8+ T cell immune responses. Yet, all test vaccines allow for an equally efficient priming of B8R20–27
specific CD8+ T cells. This observation is in accordance with the results from other studies suggesting
VACV early proteins as major source for virus-specific CD8+ T cell determinants in mice [27,28,45].
We previously showed that virus-specific CD8+ T cells serve as essential component for a rapidly
protective immune response against ECTV challenge infection [3]. Indeed, when comparing the
efficacy of MVA-∆E3L, MVA-∆F1L or MVA we revealed full protection with vaccines given just two
days prior to the lethal ECTV infection. Of note, we can assume that the immune mechanism of
rapid protection is different to that in conventional protective vaccination. The unimpaired efficacy
of MVA-∆E3L in rapidly protective vaccination is best explained by the fact that protection in this
mousepox model is solely based on rapidly activated T cell immunity. In contrast, the conventional
vaccination with MVA-∆E3L cannot protect against a harsh lethal lung infection presumably due to the
failure to elicit essential antibody responses in addition to T cell immunity. The mousepox challenge
infection in a time range very close to the MVA immunization greatly enhances the development of
antiviral immunity allowing for efficient ECTV clearance. This scenario seems to compensate for the
apparently impaired ability of the MVA-∆E3L vaccine to establish or maintain protective levels of
immunity at twenty-one days post immunization. Currently, the immune correlate(s) for the deficiency
of MVA-∆E3L immunization are unclear. MVA-∆E3L might fail to produce the target antigens for
essential immune response or it induces insufficient virus-specific memory responses. Worth again
mentioning is that the MVA infection in absence of the immune regulatory protein E3 will result in a
potent activation of innate immune responses [32,33]. Thus, MVA-∆E3L as a candidate vaccine might
be further considered for CD8+ T cell priming and potentially for superior delivery of recombinant T
cell antigens.
5. Conclusions
Our study in an experimental murine model for human smallpox suggests that MVA vaccines
with inactivated regulatory genes E3L or F1L efficiently prime antigens-specific CD8+ T cells, allow
for rapidly protective immunization against a lethal ECTV infection but do not improve the overall
protective efficacy of MVA in conventional vaccination against a harsh respiratory ECTV challenge.
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